RVMD

Revolution Medicines (RVMD) is the lead sponsor of 12 active clinical trials listed on ClinicalTrials.gov^[4], including 4 Phase 3^[1], 5 Phase 2^[2], 8 Phase 1^[3].

Trial NCT07252232^[5] evaluates daraxonrasib in Pancreatic Cancer with a target enrollment of 500 participants. Trial NCT07491445^[6] evaluates daraxonrasib in Pancreatic Cancer with a target enrollment of 900 participants. Trial NCT06881784^[7] evaluates daraxonrasib in NSCLC (Non-small Cell Lung Cancer) with a target enrollment of 420 participants.

RVMD has 8 Form 4 insider filings recorded at the SEC in the past 30 days^[8].